FASN and neoplasm: The completely lack of anti-tumor efficacy of navitoclax/ABT-263 and venetoclax/ABT-199 as single agents was fully circumvented when FASN activity was pharmacologically targeted in BT-474 tumor xenografts; thus, when administered in combination with the FASNi TVB-3664, navitoclax/ABT-263 and venetoclax/ABT-199 caused strong tumor growth inhibition (80% and 78%, respectively; Fig. 5a).